Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 28;11:545980. doi: 10.3389/fimmu.2020.545980

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Miao, Zhang, Zheng, Zhang, Lv, Guo, Xu, Han, Chen and Zhu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Therapeutic effects of anti-CD147mAb in CIA model. (A) Experimental scheme for the analysis of CIA model. C57BL/6 mice were immunized on days 0 and 21, and treated with anti-mouse CD147 mAb (CD147 mAb) or isotype control mAb (Iso) at every other day for 10 days starting on day 21. (B) Representative hind paws from normal mice (Control), Iso and CD147 mAb treatment CIA mice (Day 31). The average thickness of both hind paws was measured (n = 4). (C) The mean arthritis index in CIA mice that were administrated Iso or CD147 mAb (n = 4). (D) Percentages of Th17, Th1 and Th17/Th1 cell in the PB, spleens (Spl) and draining lymph nodes (DLN) from Control and CIA mice treated with Iso or CD147 mAb (n = 4). *P < 0.05; **P < 0.01.